Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Transmedics Group Inc (NASDAQ: TMDX) was $67.69 for the day, down -1.23% from the previous closing price of $68.53. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 0.93 million shares were traded. TMDX stock price reached its highest trading level at $69.67 during the session, while it also had its lowest trading level at $67.235.
Ratios:
Our analysis of TMDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 8.30. In the meantime, Its Debt-to-Equity ratio is 2.27 whereas as Long-Term Debt/Eq ratio is at 2.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 03 ’25 when Khayal Tamer I sold 2,407 shares for $76.43 per share. The transaction valued at 183,967 led to the insider holds 36,042 shares of the business.
Gordon Stephen bought 5,942 shares of TMDX for $389,855 on Mar 04 ’25. On Jan 07 ’25, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 1,083 shares for $80.05 each. As a result, the insider received 86,694 and left with 20,843 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2278607872 and an Enterprise Value of 2460242432. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 67.01, and their Forward P/E ratio for the next fiscal year is 30.10. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.16 while its Price-to-Book (P/B) ratio in mrq is 9.95. Its current Enterprise Value per Revenue stands at 5.572 whereas that against EBITDA is 42.971.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.13, which has changed by -0.08004892 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is -1.35%, while the 200-Day Moving Average is calculated to be -39.43%.
Shares Statistics:
TMDX traded an average of 1.83M shares per day over the past three months and 962980 shares per day over the past ten days. A total of 33.62M shares are outstanding, with a floating share count of 32.43M. Insiders hold about 3.67% of the company’s shares, while institutions hold 111.41% stake in the company. Shares short for TMDX as of 1740700800 were 9330007 with a Short Ratio of 5.10, compared to 1738281600 on 11129933. Therefore, it implies a Short% of Shares Outstanding of 9330007 and a Short% of Float of 33.69.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
